Key facts
- It has raised $410K; the latest was Accelerator/Incubator in Dec 2025.
- Notable investors include Japan Finance Corporation, Full Commit Partners, Partners Fund, LINK-J, TGA-DeepTech-2025 — 7 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 7 names
- ·Watchlist + deal alerts for Bionto
- ·The full record, as it builds
Funding rounds
No funding rounds for Bionto are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Bionto
Developer of a drug administration system designed to provide drugs non-invasively through the skin. The company specializes in the development of transdermal drug delivery systems and research into biobatteries using bio-derived materials and the usage of bioiontronics technology, enabling clients to administer large amounts at high speed and to collect subcutaneous tissue fluid.
- Sector
- Healthcare
- HQ
- Sendai, Japan
- Founded
- 2025
- Employees
- 10
- Website
- bionto.co.jp/
- Ownership
- Privately Held (backing)
Bionto doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Bionto shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Bionto in its N-PORT filings yet. We sweep new filings monthly.